Baqsimi’s NHI Tag Doubled on Foreign Price Adjustment, Payer Rep Questions Rule

Eli Lilly Japan’s Baqsimi (glucagon), an emergency treatment for hypoglycemia to be listed later this month, saw its final NHI price double from its cost-based price following an adjustment with foreign prices. Now, a vocal reimbursement panel member is calling...read more